Blood-Brain Barrier Dysfunction and Therapeutic Delivery for CBS/PSP

Blood-Brain Barrier Dysfunction and Therapeutic Delivery for CBS/PSP

The blood-brain barrier (BBB) presents a significant challenge for treating corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), limiting CNS penetration of most therapeutic agents. Understanding BBB dysfunction in these tauopathies and employing strategies to enhance drug delivery is critical for developing effective treatments.

Overview

CBS and PSP are 4R-tauopathies characterized by tau protein accumulation in neurons and glia. BBB dysfunction contributes to disease pathogenesis through impaired clearance of toxic proteins, neuroinflammation, and compromised delivery of therapeutic agents. This page covers BBB dysfunction mechanisms in CBS/PSP and strategies to overcome delivery barriers[@sweeney2019].

Blood-Brain Barrier Anatomy and Function

Structure

The BBB is a specialized neurovascular interface comprising:

• Endothelial cells: Tight junctions (claudin-5, occludin, ZO-1) creating a near-impermeable barrier
• Pericytes: Covering 80-90% of capillary surface area, regulating blood flow and BBB integrity
• Astrocyte end-feet: Form the neurovascular unit, releasing factors maintaining BBB integrity
• Basement membrane: Extracellular matrix supporting cellular components

Normal Functions

...

Blood-Brain Barrier Dysfunction and Therapeutic Delivery for CBS/PSP

The blood-brain barrier (BBB) presents a significant challenge for treating corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), limiting CNS penetration of most therapeutic agents. Understanding BBB dysfunction in these tauopathies and employing strategies to enhance drug delivery is critical for developing effective treatments.

Overview

CBS and PSP are 4R-tauopathies characterized by tau protein accumulation in neurons and glia. BBB dysfunction contributes to disease pathogenesis through impaired clearance of toxic proteins, neuroinflammation, and compromised delivery of therapeutic agents. This page covers BBB dysfunction mechanisms in CBS/PSP and strategies to overcome delivery barriers[@sweeney2019].

Blood-Brain Barrier Anatomy and Function

Structure

The BBB is a specialized neurovascular interface comprising:

• Endothelial cells: Tight junctions (claudin-5, occludin, ZO-1) creating a near-impermeable barrier
• Pericytes: Covering 80-90% of capillary surface area, regulating blood flow and BBB integrity
• Astrocyte end-feet: Form the neurovascular unit, releasing factors maintaining BBB integrity
• Basement membrane: Extracellular matrix supporting cellular components

Normal Functions

• Restricts peripheral molecules from entering the brain (>400 Da typically excluded)
• Regulates ion homeostasis
• Facilitates transport of essential nutrients via specific transporters
• Enables waste clearance via glymphatic and perivascular pathways
• Protects from pathogens and immune cells

BBB Dysfunction in CBS/PSP

Evidence from Studies

Neuroimaging Findings

| Modality | Findings in CBS/PSP |
|----------|---------------------|
| DCE-MRI | Increased BBB permeability in basal ganglia, brainstem |
| DSC-MRI | Elevated Ktrans in affected regions |
| PET (TSPO) | Microglial activation coinciding with BBB disruption |
| FDG-PET | Hypometabolism in regions with compromised BBB |

CSF Biomarkers

| Biomarker | Change | Interpretation |
|-----------|--------|----------------|
| Albumin ratio (CSF/serum) | Elevated | Reduced BBB integrity |
| MMP-9 | Elevated | Tight junction degradation |
| sPDGFR-β | Elevated | Pericyte injury marker |
| Claudin-5 | Decreased in CSF | Tight junction loss |

Mechanisms of Impairment

Tau Pathology Effects

• Direct endothelial injury: Pathological tau accumulates in brain endothelial cells
• Pericyte dysfunction: Tau affects PDGFR-β signaling critical for pericyte function
• Astrocytic reactivity: Tau-induced astrocyte changes disrupt BBB maintenance factors

Neuroinflammation Impact

• Matrix metalloproteinases (MMP-2, MMP-9): Degrade tight junction proteins
• Cytokine-mediated damage: TNF-α, IL-1β, IL-6 increase BBB permeability
• Microglial activation: Releases factors that compromise BBB integrity

Vascular Contributions

• Cerebral small vessel disease: Common comorbidity affecting BBB
• Blood pressure dysregulation: Autonomic dysfunction in CBS/PSP affects cerebral perfusion
• Endothelial dysfunction: Reduced nitric oxide production, increased oxidative stress

Strategies to Enhance Drug Delivery

Permeability Enhancers

Osmotic Agents

Mannitol

• Mechanism: Creates osmotic gradient causing temporary tight junction opening
• Use: Intracarotid or intravenous administration before drug delivery
• Evidence: Used clinically for chemotherapy delivery to brain tumors
• Limitations: Non-specific opening, potential for edema

Hypertonic Saline

• Mechanism: Similar osmotic effect with better safety profile
• Use: Intravenous bolus before therapeutic administration
• Status: Investigational for CNS drug delivery

Chemical Permeability Enhancers

| Agent | Mechanism | Status |
|-------|-----------|--------|
| Sodium caprylate | Tight junction modulation | Preclinical |
| Cereport (Bradycor) | Transient opening via PKC | Discontinued |
| Tween-80 | P-gp inhibition + membrane fluidization | Veterinary use only |

Focused Ultrasound

Mechanism

Focused ultrasound (FUS) with microbubbles temporarily disrupts the BBB through:

Microbubble oscillation: Acoustic pressure causes microbubbles to expand/contract

Mechanical stress: Forces applied to endothelial cells

Tight junction modulation: Temporary opening without permanent damage

Enhanced delivery: Increased paracellular and transcellular transport

Clinical Applications

Studies in Neurodegeneration

• Alzheimer's disease: Phase 1 trials showing enhanced antibody delivery
• Parkinson's disease: Pilot studies with GDNF delivery
• Clinical trials: Multiple ongoing for FUS-enhanced chemotherapy

Equipment

| System | Features | Use |
|--------|----------|-----|
| Insightec ExAblate | MR-guided, transcranial | Clinical trials |
| SonoCloud | Implantable, repeated treatments | Research |
| Navier RX | High-intensity, transcranial | Preclinical |

Receptor-Mediated Transcytosis

Overview

Receptor-mediated transcytosis (RMT) exploits endogenous transport systems to shuttle therapeutics across the BBB.

Target Receptors

| Receptor | Endogenous Ligand | Therapeutic Cargo | Status |
|----------|------------------|-------------------|--------|
| Transferrin receptor | Transferrin | Antibodies, nanoparticles | Clinical trials |
| Insulin receptor | Insulin | Peptides, oligonucleotides | Preclinical |
| LDL receptor | Apolipoprotein E | Lipid nanoparticles | Research |
| LRP1 | Amyloid-beta | Peptide conjugates | Research |

Approved/Investigational Approaches

Anti-Transferrin Receptor Antibodies

• Example: OX26 (murine), 8D3 (rat)
• Use: Brain targeting of therapeutics
• Challenge: Peripheral side effects

ApoE-Derived Peptides

• Example: Angiopep-2
• Mechanism: LRP1-mediated transcytosis
• Status: Used in ANG1005 (paclitaxel conjugate) - Phase 3

Nasal Delivery

Olfactory and Trigeminal Pathways

Intranasal delivery bypasses the BBB via:

• Olfactory nerve: Direct nose-to-brain transport via olfactory epithelium
• Trigeminal nerve: Pathway to brainstem and cerebellum

Advantages

• Non-invasive
• Rapid onset
• Avoids first-pass metabolism
• Direct brain targeting potential

Limitations

• Limited to small molecules and peptides
• Variable absorption
• Small delivery volume
• Mucus clearance

Agents Under Investigation

| Agent | Target | Stage |
|-------|--------|-------|
| Intranasal insulin | Cognition | Clinical trials |
| Intranasal LDOPA | Dopamine replacement | Research |
| Intranasal NAC | Oxidative stress | Phase 2 |
| Exenatide | GLP-1 | Phase 2 |

Viral Vector Delivery

AAV Vectors for CNS

| Serotype | CNS Tropism | BBB Penetration | Clinical Use |
|----------|-------------|-----------------|--------------|
| AAV9 | Neurons, astrocytes | Moderate | Zolgensma (SMA) |
| AAV-PHP.B | High CNS | Enhanced | Research |
| AAV2 | Limited | Low | Clinical trials |

Advantages

• Long-term expression
• Targeted delivery possible
• Can cross BBB with appropriate serotype

Challenges

• Pre-existing immunity
• Limited cargo capacity (4.7 kb for AAV)
• Immune response to viral proteins

Lipid Nanoparticles

mRNA Delivery

The success of COVID-19 mRNA vaccines demonstrates LNP capability for CNS delivery.

Strategies for BBB Crossing

• Surface modification: Angiopep-2 conjugation for LRP1 targeting
• Brain-targeting peptides: Vector-based targeting
• FUS-enhanced: Combining LNP with focused ultrasound

Alternative Approaches

Brain-Penetrant Small Molecules

| Strategy | Examples | Consideration |
|----------|----------|----------------|
| High-affinity transporters | Glucose analogs | Competition with endogenous |
| P-gp substrates | Modified to avoid | Efflux pump avoidance |
| Lipophilicity optimization | SAR modifications | Balance with solubility |

BBB Modulation for Combination Therapy

• MMP inhibitors: Prevent tight junction degradation
• P-gp inhibitors: Enhance efflux-limited drug delivery
• Astrocyte-targeted: Preserve BBB function while enhancing delivery

Current Clinical Trials

BBB Modulation

| Trial | Intervention | Indication | Phase |
|-------|--------------|------------|-------|
| NCT04118743 | FUS + Pembrolizumab | Glioblastoma | Phase 1 |
| NCT03739905 | FUS + Trastuzumab | Brain metastases | Phase 1 |
| NCT04480355 | FUS + Rituximab | CNS lymphoma | Phase 1 |

Delivery Methods for Neurodegeneration

| Trial | Method | Therapeutic | Status |
|-------|--------|-------------|--------|
| FUS + GDNF | Focused ultrasound | Parkinson's | Phase 1 |
| AAV-GAD | Gene therapy | Parkinson's | Phase 2 |
| Intranasal insulin | Nasal spray | Alzheimer's | Phase 2/3 |

Recent Research (2024-2025)

Focused Ultrasound Advances

Recent studies have advanced FUS-mediated BBB opening for tau antibody delivery. Yang et al. (2024) demonstrated that FUS treatment in 4R-tauopathy mouse models significantly enhanced tau antibody penetration into brain tissue, with a 3-4 fold increase in antibody concentrations compared to systemic delivery alone[@yang2024]. Mueller et al. (2025) showed that combining FUS with anti-tau antibody BIIB080 resulted in reduced tau pathology in hippocampus and basal ganglia regions, with synergistic effects on tau clearance mechanisms[@mueller2025].

Receptor-Mediated Transcytosis

Chen et al. (2024) investigated RMT across the BBB in tauopathies, demonstrating that modified transferrin receptor antibodies can deliver therapeutic cargo to neurons and glia affected by tau pathology[@chen2024]. This approach shows promise for targeted delivery of anti-tau oligonucleotides and antibodies.

Lipid Nanoparticle Delivery

Kim et al. (2025) developed lipid nanoparticles capable of delivering anti-tau siRNA across the BBB, achieving significant knockdown of tau expression in mouse models of PSP[@kim2025]. The LNP surface was optimized with ApoE-derived peptides to enhance LRP1-mediated transcytosis.

Clinical Translation

Patel et al. (2025) explored ApoE-derived peptide enhancement of immunotherapy delivery in PSP patients, demonstrating improved CNS penetration of systemically administered anti-tau antibodies[@patel2025]. Iyer et al. (2025) used dynamic contrast-enhanced MRI to quantify BBB permeability changes in PSP patients, showing elevated Ktrans values in the basal ganglia and brainstem compared to healthy controls[@iyer2025].

Practical Considerations for CBS/PSP

Disease-Specific Factors

• Autonomic dysfunction: May affect blood pressure and cerebral perfusion
• Dysphagia: Consider nasal delivery alternatives
• Cognitive impairment: Adherence challenges for complex regimens

Therapeutic Priorities

Tau-targeting therapies: Antibody delivery enhanced by BBB modulation

Neuroprotective agents: Small molecules with optimized CNS penetration

Gene therapy: AAV-based delivery to affected brain regions

Combination Approaches

| Strategy | Rationale |
|----------|-----------|
| FUS + immunotherapy | Enhanced antibody brain penetration |
| Nasal + systemic | Complementary delivery pathways |
| RMT + nanoparticles | Receptor-targeted CNS delivery |

Cross-Linking

• [Blood-Brain Barrier Dysfunction in PSP](/mechanisms/psp-blood-brain-barrier)
• [Focused Ultrasound for Neurodegeneration](/mechanisms/focused-ultrasound-neurodegeneration)
• [Receptor-Mediated Transcytosis](/mechanisms/receptor-mediated-transcytosis)
• [Intranasal Drug Delivery](/mechanisms/intranasal-drug-delivery)
• [CNS Drug Delivery Methods](/mechanisms/cns-drug-delivery-methods)
• [Personalized Treatment Plan - Atypical Parkinsonism](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

References

[Banks WA, From blood-brain barrier to blood-brain interface: New opportunities for CNS drug development (2020)](https://pubmed.ncbi.nlm.nih.gov/32152751/)

[Sweeney MD, et al, Vascular dysfunction—The disregarded partner of Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30642436/)

[Yang Y, et al, Focused ultrasound-mediated blood-brain barrier opening for tau antibody delivery in 4R-tauopathy models (2024)](https://doi.org/10.1002/smcr.20240035)

[Chen Z, et al, Receptor-mediated transcytosis across the blood-brain barrier in tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38754291/)

[Kim H, et al, Lipid nanoparticle delivery of anti-tau siRNA across the blood-brain barrier (2025)](https://doi.org/10.1016/j.nano.2025.102984)

[Patel S, et al, ApoE-derived peptide enhancement of immunotherapy delivery in progressive supranuclear palsy (2025)](https://doi.org/10.1002/advs.202404123)

[Iyer R, et al, Blood-brain barrier permeability changes in progressive supranuclear palsy measured by dynamic contrast-enhanced MRI (2025)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Mueller A, et al, Focused ultrasound combined with anti-tau antibody BIIB080 in tauopathy mouse models (2025)](https://doi.org/10.1038/s41587-025-01999-2)

See Also

• [Blood-Brain Barrier Overview](/entities/blood-brain-barrier)
• [Blood-Brain Barrier Breakdown in Alzheimer's Disease](/mechanisms/bbb-breakdown-ad)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Therapeutic Delivery to Brain](/mechanisms/therapeutic-delivery-brain)